<DOC>
	<DOC>NCT01368536</DOC>
	<brief_summary>This was a study to assess the safety and efficacy of Valturna and amlodipine or Valturna and chlorthalidone when compared to Valturna alone in patients with stage 2 hypertension and diabetes mellitus 2.</brief_summary>
	<brief_title>Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Chlorthalidone</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Patients with stage 2 hypertension within protocol limits at randomization Patients with type 2 diabetes mellitus with HgA1c less than or equal to 9% Patients with newly diagnosed hypertension or patients who have not received antihypertensive therapy for at least 4 weeks prior to screening Patients taking 4 or more antihypertensive medications at screening visit Patients with uncontrolled BP (&gt; 140/90 mmHg) while taking 3 or more antihypertensives at their maximum approved doses Type 2 diabetes mellitus requiring insulin treatment Patients with HgA1c &gt; 9% Patients with known gout Known history of cancer within the past 5 years Patients who are pregnant or nursing mothers Patients who have participated in an investigational clinical trial within the 30 days prior to screening. Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>High blood pressure</keyword>
	<keyword>diabetes</keyword>
</DOC>